Chimeric Antigen Receptor (car) - Toxicology

Relevant Publications

Dermatologic adverse events associated with chimeric antigen receptor T-cell therapy: a pharmacovigilance analysis of the FDA reporting system.

Issue Release: 2024

Clinical and Genomic Profile of Primary Cranial Neurolymphomatosis.

Issue Release: 2024

Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management.

Issue Release: 2024

Steering the course of CAR T cell therapy with lipid nanoparticles.

Issue Release: 2024

Current trends and outcomes in cellular therapy activity in the United States, including prospective Patient Reported Outcomes data collection within the CIBMTR registry.

Issue Release: 2024

CAR-T cell therapy: Efficacy in management of cancers, adverse effects, dose-limiting toxicities and long-term follow up.

Issue Release: 2024

CAR macrophages tuning the immune symphony of anti-cancer therapies.

Issue Release: 2024

The CDK9 inhibitor enitociclib overcomes resistance to BTK inhibition and CAR-T therapy in mantle cell lymphoma.

Issue Release: 2024

Endothelial injury and dysfunction with emerging immunotherapies in multiple myeloma, the impact of COVID-19, and endothelial protection with a focus on the evolving role of defibrotide.

Issue Release: 2024

Regulatory landscape and challenges in CAR-T cell therapy development in the US, EU, Japan, and India.

Issue Release: 2024

Cholesterol efflux from C1QB-expressing macrophages is associated with resistance to chimeric antigen receptor T cell therapy in primary refractory diffuse large B cell lymphoma.

Issue Release: 2024

Preclinical efficacy of a HER2 synNotch/CEA-CAR combinatorial immunotherapy against colorectal cancer with HER2 amplification.

Issue Release: 2024

Matching-adjusted indirect comparisons of axicabtagene ciloleucel to mosunetuzumab for the treatment of relapsed/refractory follicular lymphoma.

Issue Release: 2024

Options for Rescue Treatment of Patients with AL Amyloidosis Exposed to Upfront Daratumumab.

Issue Release: 2024

Moving T-Cell Therapies into the Standard of Care for Patients with Relapsed or Refractory Follicular Lymphoma: A Review.

Issue Release: 2024

The Glass Wall: Gendered Authorship Disparities in CD 19 and BCMA CAR-T Clinical Trials for Lymphoma and Myeloma.

Issue Release: 2024

PSCA-CAR T cell therapy in metastatic castration-resistant prostate cancer: a phase 1 trial.

Issue Release: 2024

Treatment of Relapsed Acute Lymphocytic Leukemia in Adult Patients.

Issue Release: 2024

Expression of VISTA regulated via IFN-γ governs endogenous T-cell function and exhibits correlation with the efficacy of CD19 CAR-T cell treated B-malignant mice.

Issue Release: 2024

4-1BB-encoding CAR causes cell death via sequestration of the ubiquitin-modifying enzyme A20.

Issue Release: 2024

What is Exposure Time?

Can Prevalence Studies Help in Disease Prevention?

What are Phthalate-Free Plasticizers?

What Role Does Hydrometallurgy Play in Toxicology?

How to Mitigate Exposure Risks?

How Can Toxicologists Ensure Adherence to Ethical Guidelines?

How Does IARC Conduct Its Evaluations?

How Can These Challenges Be Addressed?

Are There Any Differences Among Opioid Receptor Types?

How Does Genetic Variation Affect Susceptibility?

Partnered Content Networks

Relevant Topics